Slide 1: Q3 2022 Financial Results and Business Update
Q3 2022 Financial Results and Business Update November 14, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi, MD Joyson Karakunnel, MD, MSc, FACP Chief Executive Officer EVP, Chief Medical Officer Chairman of the Executive Board Yannis Morel, PhD Frédéric Lombard, MBA EVP, Business Development and SVP, Chief Financial Officer (Q&A) Product Portfolio Strategy 3
Slide 4: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Drive near-term Advance our Build sustainable value with innovative R&D business through Lacutamab pipeline partnerships • Data-driven clinical development • IPH6401 ANKETTM BCMA • PACIFIC-9 Phase 3 NSCLC start plan for PTCL underway se
Slide 5: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Comments Sézary syndrome TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data at ASH 2022 Mycosis Fungoides TELLOMAK Preliminary Phase 2 data presented EORTC 2022
Slide 6: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary syndrome (N~60) Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2# Cohort 3# All Comers* All comers, SS, must include KIR3DL
Slide 7: Encouraging Preliminary Results in KIR3DL2-Expressing Mycosis Fungoides Cohort of TELLOMAK trial
LACUTAMAB Encouraging Preliminary Results in KIR3DL2-Expressing Mycosis Fungoides Cohort of TELLOMAK trial Stage 1 results in MF patients with at least 2 prior line therapy Cohort 2 Cohort 3 KIR3DL2 expressors (n=21) KIR3DL2 non expressors (n=18) Skin Skin N % [95%CI] N % [95%CI] Global ORR 6 (2CR;
Slide 8: ASH abstract - Preliminary lacutamab Sézary syndrome Phase 2 data
LACUTAMAB ASH abstract - Preliminary lacutamab Sézary syndrome Phase 2 data Preliminary Sézary syndrome Phase 2 TELLOMAK data, final data due in 2023 Patient baseline characteristics 37 post mogamulizumab patients with advanced, highly refractory and heavily pre-treated disease 6 median lines of pri
Slide 9: Developing a New Standard of Care Across KIR3DL2 Expressing T-Cell Lymphomas
LACUTAMAB Developing a New Standard of Care Across KIR3DL2 Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sézary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients
Slide 10: Monalizumab: Early NSCLC
MONALIZUMAB Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* Stg I-IIIA NSCLC Unresect. Stg III NSCLC monali
Slide 11: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ is a versatile, fit-for- purpose technology that is creating an entirely new class of tri- and tetra-specific molecules to induce synthetic immunity against cancer TAg: Tumor antigen Gauthier et al. Cell 2019 ; Demaria et al., Cell
Slide 12: ANKET molecules control tumor proliferation via proliferation and activation of NK cells
ANKETTM ANKET™ molecules have the potential to strongly control tumor proliferation via the proliferation and activation of NK cells NK cells are proven anti-tumor cells Innate Pharma differentiated MoA Strong preclinical activity Tetraspecific ANKET Cytokine production Tumor cell NK cell Killing NK
Slide 13: Two molecules from Innate ANKET engine selected by Sanofi
ANKETTM Two molecules from Innate ANKETTM engine selected by Sanofi Anti-CD123 IPH6101/SAR’579 currently in Phase 1 in AML ; Anti-BCMA IPH6401/SAR’514 progressing toward IND Multispecific antibody engineering targeting a tumor antigen, NKp46 and CD16a IPH6101/SAR’579 IPH6401/SAR’514 €13M milestone p
Slide 14: Presentations at the ASH 2022 Annual Congress
Presentations at the ASH 2022 Annual Congress What will be presented? Publications December 2022 October 2022 Lacutamab Phase 2 SS Cohort 1 Antibody-Based NK Cell Engager Therapeutics IPH6101 (CD123 ANKET) (Sanofi) IPH6401 (BCMA ANKET) (Sanofi) Tetraspecific antibodies from ANKETs highlighted in Oct
Slide 15: Upcoming catalysts
Upcoming catalysts Delivering across our strategic objectives • Monalizumab PACIFIC-9 | Phase 3 readout • Monalizumab NeoCOAST-2 | Phase 2 readout • IPH5201 (CD39) MATISSE | Phase 2 readout • IPH6501 ANKETTM (CD20) | IND Filing • IPH6501 ANKETTM (CD20) | Phase 1 data • IPH6401 ANKETTM (BCMA) | IND •
Slide 16: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Lacutamab R&D pipeline Partnerships • TELLOMAK preliminary data • Advancing proprietary CD20 tetra- • Phase 3 monalizumab presentations in MF and SS in specific NK cell-targeted platform collaboration with AstraZeneca 2022 and portfolio
Slide 17: Questions and Answers
Questions and Answers &S innate pharma